European Journal of Hospital Pharmacy · 2022 · 23 citations · 19 references
PharmacyPharmacologyPharmacotherapyAntimicrobial PharmacotherapyClinical PharmacologyGeriatric PharmacotherapyAntibiotic Use In Older AdultsDrug Safety MonitoringMedication UseCohort Study InvestigationElectronic Medical RecordsGram-positive Bacterial InfectionsLinezolid TherapyLogistic RegressionOxazolidinone AntibioticsOxazolidinone TherapyPrediction Model Development
OBJECTIVES: Linezolid is the first oxazolidinone antimicrobial agent developed for treating multi-drug-resistant gram-positive bacterial infections. The study aimed to investigate the risk factors of linezolid (LI)-induced thrombocytopenia (LI-TP) and to develop and validate a risk prediction model to identify elderly patients at high risk of developing LI-TP during linezolid therapy. METHODS: A retrospective cohort study was performed at Zhongshan Hospital, FuDan University, China. The study involved elderly Chinese patients aged ≥65 years administered with linezolid (600 mg) twice a day between January 2015 and April 2021. We collected the patients' clinical characteristics and demographic data from electronic medical records, and compared the differences between LI-TP patients and those who had not developed thrombocytopenia (NO-TP) after linezolid treatment. The risk prediction model was developed based on the regression coefficient generated from logistic regression model. RESULTS: (OR=2.553; p=0.002), duration of linezolid therapy ≥10 d (OR=3.218; p<0.001), intensive care unit (ICU) admittance (OR=2.682; p=0.004), concomitant piperacillin-tazobactam (OR=3.863; p=0.006) were independent risk factors for LI-TP in elderly patients. The LI-TP risk prediction model was established using a scoring method based on the regression coefficient and exhibited a good discriminative power, with an area under the curve (AUC) of 0.795 (95% confidence interval (CI) 0.740 to 0.851) and 0.849 (95% CI 0.760 to 0.939) in the training set (n=343) and validation set (n=90) respectively. CONCLUSIONS: These findings indicate that duration of linezolid therapy, age, eGFR, ICU admittance, baseline platelet counts, concomitant piperacillin-tazobactam were significantly associated with LI-TP in elderly patients. A risk prediction model based on these risk factors showed a good discriminative performance and may be useful for clinicians to identify patients at high risk of developing LI-TP.
19
Mechanisms for Linezolid-Induced Anemia and Thrombocytopenia
Wendy B. Bernstein, Richard F. Trotta, James T. Rector et al. · Annals of Pharmacotherapy · 2003 · 183 citations
Thrombocytopenia and outcome in critically ill patients with bloodstream infection
Dominique Vandijck, Stijn Blot, Jan J. De Waele et al. · Heart & Lung · 2009 · 153 citations
T. Sasaki, Hiroshi Takane, Katsuhiro Ogawa et al. · Antimicrobial Agents and Chemotherapy · 2011 · 138 citations · Full text